Cargando…

LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1

The role of programmed cell death ligand 1 (PD-L1) in suppressing antitumor immune responses has been widely reported, and recent studies showed that PD-L1 also plays an important role in epithelial-mesenchymal transition (EMT), determination of tumor cell phenotypes, metastasis, and drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Zhijia, Xue, Chunyuan, Li, Jiangbo, Zhao, Hui, Du, Yimeng, Du, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974003/ https://www.ncbi.nlm.nih.gov/pubmed/35266439 http://dx.doi.org/10.1080/21655979.2022.2050073

Ejemplares similares

Downregulated Reprimo by LINC00467 participates in the growth and metastasis of gastric cancer
por: Wu, Yuanyuan, et al.
Publicado: (2022)

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination
por: Sun, Zhijia, et al.
Publicado: (2023)

LINC00052 suppressed glioma cell proliferation and invasion by downregulating insulin-like growth factor 2
por: Piao, Yinzi, et al.
Publicado: (2019)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
por: Li, Chia-Wei, et al.
Publicado: (2016)

Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence
por: Li, Jiangbo, et al.
Publicado: (2022)

Downregulation of LINC01857 Increases Sensitivity of Gastric Carcinoma Cells to Cisplatin
por: Chen, Yun, et al.
Publicado: (2022)

Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells
por: Du, Haiyan, et al.
Publicado: (2023)

Corrigendum to: Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2020)

lncRNA LINC-PINT is downregulated in melanoma and regulates cell proliferation by downregulating lncRNA BANCR
por: Huang, Qing, et al.
Publicado: (2019)

LINC00460 Stimulates the Proliferation of Vascular Endothelial Cells by Downregulating miRNA-24-3p
por: Jia, Ruofei, et al.
Publicado: (2022)

Retracted: Downregulation of LINC01857 Increases Sensitivity of Gastric Carcinoma Cells to Cisplatin
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Downregulation of lncRNA ANRIL suppresses growth and metastasis in human osteosarcoma cells
por: Guan, Hongya, et al.
Publicado: (2018)

Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transition
por: Wang, Jing, et al.
Publicado: (2015)

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
por: Rozali, Esdy N., et al.
Publicado: (2012)

ADAMTS8 targets ERK to suppress cell proliferation, invasion, and metastasis of hepatocellular carcinoma
por: Zhao, Xuetao, et al.
Publicado: (2018)

Corylin suppresses metastasis of breast cancer cells by modulating miR-34c/LINC00963 target
por: Liu, Shourong, et al.
Publicado: (2021)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression
por: Du, Liuxue, et al.
Publicado: (2018)

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

E2F1 combined with LINC01004 super-enhancer to promote hepatocellular carcinoma cell proliferation and metastasis
por: Li, Jingxuan, et al.
Publicado: (2023)

Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory
por: Kazanova, Alexandra, et al.
Publicado: (2021)

Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports
por: Liu, Shao-Ru, et al.
Publicado: (2021)

Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
por: Chen, Man-Chin, et al.
Publicado: (2019)

Downregulation of LINC00115 inhibits the proliferation and invasion of lung cancer cells in vitro and in vitro
por: Shao, Lili, et al.
Publicado: (2021)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
por: Zeng, Linyan, et al.
Publicado: (2022)

Cisplatin‐induced programmed cell death ligand‐2 expression is associated with metastasis ability in oral squamous cell carcinoma
por: Sudo, Shunichi, et al.
Publicado: (2020)

FOXK2 downregulation suppresses EMT in hepatocellular carcinoma
por: Kong, Jian, et al.
Publicado: (2020)

ADAM23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cells
por: Ota, Masahide, et al.
Publicado: (2016)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
por: Chen, Zhifang, et al.
Publicado: (2016)

LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway
por: Zheng, Yin-Li, et al.
Publicado: (2019)

Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells
por: Zhang, Shuhong, et al.
Publicado: (2009)

LINC-DUBR Suppresses Malignant Progression of Ovarian Cancer by Downregulating miR-107 to Induce SMAC Expression
por: Han, Zhehui, et al.
Publicado: (2022)

Novel prognostic marker LINC00205 promotes tumorigenesis and metastasis by competitively suppressing miRNA-26a in gastric cancer
por: Huangfu, Longtao, et al.
Publicado: (2022)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i4ncd33tbkdqkekh58hejsfba4